Wider use of beta-blockers after heart attacks could save thousands of lives at a reasonable cost, new study shows

December 05, 2000

Thousands of lives would be spared if physicians prescribed beta-blockers for more people who have had heart attacks, according to a new study led by researchers at the University of California San Francisco (UCSF).

Providing beta-blockers to most people who have had heart attacks would save seven times more years of life by 2020 than will be saved through mammography screening of a similar-sized population every year over the next two decades, the researchers report in the December 6 issue of the Journal of the American Medical Association (JAMA).

Their study projects more than 4,000 lives saved from coronary disease and 3,500 heart attacks averted over 20 years at a reasonable cost simply by providing beta-blockers to those who are "eligible" among current heart attack survivors - about 92 percent of those with heart attacks.

"Most clinicians and other health professionals have known for ten years or more that beta-blockers can play a dramatic role in saving lives and sparing more heart attacks, but for a combination of reasons, the practice has not been widely adopted," said Kathryn A. Phillips, PhD, lead author on the study and associate professor of health economics and health services research in the UCSF clinical pharmacy department, School of Pharmacy.

"I hope this study proves to be an impetus to increase the use of beta-blockers for all those who can benefit from them."

Senior author on the study is Lee Goldman, MD, MPH, professor and chair of medicine at UCSF.

The research draws on a well-respected model of cardiac health disease in the U.S., known as the Coronary Heart Disease Policy Model, which incorporates national census data and the principal known health risk factors for heart disease. The model has been validated by comparing predicted mortality against actual mortality and has been shown to predict outcomes within two percent.

The National Center for Quality Assurance, which accredits managed care organizations, considers use of beta-blockers as an indicator of high-quality health care, but a combination of public misapprehensions about side effects, heavy marketing of related drugs, and uncertainty among some physicians has stalled widespread use of beta-blockers, Phillips explained.

Serious side effects - fatigue, sexual dysfunction and depression - are uncommon, probably occurring in less than one-tenth of patients, but the "word on the street" seems to be that the frequency of side effects is much higher, Phillips said. In addition, drug manufacturers aggressively market and physicians widely prescribe a more expensive, related class of drugs - calcium channel blockers -- although many physicians don't realize that these medications are not appropriate substitutes for beta-blockers, Phillips added.

Beta-blockers - technically beta-adrenergic blocking agents - are prescribed to treat high blood pressure and angina pain, and they are used for heart failure and after heart attacks. They work by blocking the stimulation of certain receptors which reduces the heart rate and decreases the strength of the heart's contraction.

The study projected the benefits in decreased disease and lives saved by providing beta-blockers to all who have had heart attacks except those with the most severe conditions or who are allergic to the medicine. This is about 92 percent of heart attack survivors, or about 400,000 people annually in the U.S.

Because beta-blockers are available as generic drugs, the researchers found that such an increase in prescribing beta-blockers would not be prohibitively costly. The net cost was estimated to be $158 million. However, since beta-blockers can be purchased as generics for less than $300 per person annually, their increased use would actually save money over the 20 years studied due to lower medical costs.

"The value of beta-blockers has already been clinically proven," said Phillips. "But what has not been as clear is the value from a societal perspective. This study goes a long way to show that increased use of beta-blockers to the target population will save lives at a reasonable cost, and in some cases, will save money."

"Our study re-emphasizes the 'lost opportunity' that results from the under-use of medications that are both effective and cost-effective," said Lee Goldman. "Current practice has yielded only about 55 percent of the potential benefit of beta-blockers for survivors of heart attack. It is critical that our quest for new therapies not distract us from taking fullest advantages of the already-proven ones."
Collaborators on the research and co-authors with Phillips and Goldman on the JAMA paper are Michael Shlipak, MD, MPH, assistant professor, and Pam Coxson, PhD, mathematics specialist, both in the department of medicine at UCSF; Paul Heidenreich, MD, assistant professor of medicine and cardiovascular medicine at Stanford University; M.G. Myriam Hunink, PhD, professor of clinical epidemiology, Erasmus University, The Netherlands and adjunct professor of health policy, Harvard University; Paula Goldman, MPH, specialist, and Milton Weinstein, PhD, professor of health policy and management, both at the Harvard School of Public Health; and Lawrence Williams, MS, specialist, Brigham and Women's Hospital.

University of California - San Francisco

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.